Filing Flows › Corcept Therapeutics (CORT) › Q2 2025
Corcept Therapeutics (CORT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Corcept Therapeutics (CORT) reported revenue of $194M for the second quarter 2025 (Q2 2025), +19% from a year earlier and +24% from the quarter before. Operating margin was 13.7%, net earnings $35.1M (18.1% of revenue).
Corcept Therapeutics, Q2 2025: revenue $194M (+19% year over year), operating margin 13.7%, net earnings $35.1M, operating cash flow $43.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $194M | +24% | +19% |
| Operating profit | $26.7M | +681% | -25% |
| Net earnings | $35.1M | +71% | -1% |
| Operating cash flow | $43.9M | +757% | +7% |
| Free cash flow | $43.9M | +773% | +8% |
What changed
Revenue was $194.4M in Q2 2025, up 19% year over year and up 24% from the previous quarter.
Operating profit was $26.7M, a 13.7% margin (down 8.0 points year over year). Operating profit fell $8.9M even though revenue rose $30.6M versus a year earlier, so costs grew faster than sales. Total costs grew 31% against revenue growth of 19%. The fastest-growing cost line was SG&A (+55%). Net earnings were $35.1M, down 1% year over year. The effective tax rate was -10.9%.
Operating cash flow was $43.9M (up 7% year over year), 125% of net earnings. Non-cash charges added back $286K of depreciation and amortization and $19.0M of share-based compensation. Working capital and other items used $10.5M. Capital expenditures of $57K left free cash flow of $43.9M.
Questions
What was Corcept Therapeutics' revenue in the second quarter 2025?
Corcept Therapeutics (CORT) reported revenue of $194M for the second quarter 2025 (Q2 2025), +19% from a year earlier and +24% from the quarter before.
Was Corcept Therapeutics profitable in the second quarter 2025?
Operating profit was $26.7M (13.7% of revenue) and net earnings $35.1M.